Author: Skye Bioscience, Inc.

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independent Data Safety Monitoring Committee completed fourth unblinded review with no concerns raised; CBeyondTM study continues per protocolNew preclinical study highlights superior weight rebound profile of nimacimab compared to incretin therapy.Preclinical data shows dosing nimacimab in combination withRead More

Read More

– May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) – – CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated 1H 2026 – – Combination dose escalation initiated of CX-801 masked interferon alpha-2b with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma – – Completed $100 million underwritten offering of commoRead More

Read More